Search Form

  • Home
  • Insights
  • FDA Approves Veklury (Remdesivir) for Treatment of Hospitalized COVID-19 Patients
Enlyte

FDA Approves Veklury (Remdesivir) for Treatment of Hospitalized COVID-19 Patients

November 2, 2020
1 MIN READ

Mitchell International

On October 22, 2020, the Food and Drug Administration (FDA) approved the first medication for treatment of COVID-19 patients requiring hospitalization. Veklury (remdesivir) is approved for use in adults and pediatric patients older than 12 years and weighing at least 40 kilograms (88 pounds). The approval is limited to use in hospitals or health care settings that can provide acute care equivalent to inpatient hospital care.

Veklury is an antiviral drug and showed efficacy in three clinical trials in treating patients hospitalized with COVID-19. The American College of Occupational and Environmental Medicine (ACOEM) recommends remdesivir only for supervised treatment of select COVID-19 patients. For workers' compensation, we expect this approval to have minimal impact beyond hospitalized patients.

If you have any questions about this alert, please contact your client services manager.